drugset
drugset / Trial / NCT03110549

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

NCT03110549 ↗

Phase 1 Terminated 9 enrolled TaiMed Biologics Inc.
RandomizedSequentialTriple-blindTreatment

Summary

The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

Timeline

Start
2016-11-21
Primary completion
2019-07-22
Completion
2019-07-22

Outcome

Outcome not reported

Stopped: “Drug development suspended by current holder of IND”

Drugs

EvaluationDrugModalityDoseRoute
Subject TMB-607 Small molecule 100 mg Subcutaneous
Subject TMB-607 Small molecule 200 mg Subcutaneous
Subject TMB-607 Small molecule 400 mg Subcutaneous
Subject TMB-607 Small molecule 500 mg Subcutaneous
Subject TMB-607 Small molecule 800 mg Subcutaneous
Subject TMB-607 Small molecule 1000 mg Subcutaneous
Subject TMB-607 Small molecule 1500 mg Subcutaneous

Indications

HIV infectious disease